New Rhein Healthcare Investors invites you to join us for our event, Investing in Healthcare and Life Science Innovations, in Singapore on September 17th. Learn from experienced investors and pharmaceutical executives, such as Greg Parekh (New Rhein Healthcare Investors), Carl Firth (ASLAN Pharma), and Subhanu Saxena (New Rhein Healthcare investors and Bill and Melinda Gates Foundation), and others about value investing in healthcare and strategies for investing in uncertain environments. New Rhein Healthcare Investors presents: "Investing in Healthcare and Life Science Innovations" September ..read more

Theranica's Evidence-Based Wearable Device will be Offered to Members Covered Under Harvard Pilgrim Health Care and Tufts Health Plan MONTCLAIR, N.J. and CANTON, Mass., Oct. 24, 2022 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced digitally-connected neuromodulation devices for migraine and other pain conditions, announced today it has teamed up with Point32Health, the parent organization of Harvard Pilgrim Health Care and Tufts Health Plan, to conduct a 12-month pilot aimed at treating the organization's commercial members suffering from episodic and c ..read more

https://read.houstonmethodist.org/peg-nerve-fusion-technique ..read more

Preventive Treatment of Migraine Remote Electrical Neuromodulation (REN) device Nerivio® demonstrates significant superiority over placebo, reduces mean number of migraine days per month when used every other day NETANYA, Israel and MONTCLAIR, N.J., Oct. 18, 2022 /PRNewswire/ -- Theranica Bio-electronics, a prescribed digital therapeutics company developing advanced digitally connected neuromodulation devices for migraine and other pain conditions, today announced positive top-line results in its double-blind, randomized, placebo-controlled, multi-center, pivotal clinical trial in the USA (NCT ..read more

PHILADELPHIA--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries, announced key organizational and financial updates.Evan Tzanis has been appointed to the role of Chief Operating Officer and Executive Vice President of Research and Development. Mr. Tzanis had served in the role of Executive Vice President of Research and Development since joining Neuraptive in 2019, and will continue to report to Robert Radie, Chairman ..read more

PHILADELPHIA--(BUSINESS WIRE)--Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for the treatment of peripheral nerve injuries (PNI), today announced the enrollment of the first patient in its Phase 2a clinical trial evaluating the safety and efficacy of NTX-001 compared to the standard of care in the treatment and prevention of facial paralysis. “As we continue to emerge from the global pandemic, we have seen a significant improvement in enrollment and expect topline results in the second half of ..read more

Proceeds to Fund U.S. Commercial Expansion of Migraine Treatment Device, Nerivio® Financing Led by Philadelphia-Based New Rhein Healthcare, Selected Additional Co-Investors to Join Round at Final Closing NETANYA, Israel and MONTCLAIR, N.J., Aug. 29, 2022 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other idiopathic pain conditions, today announced the closing of its Series C funding round, with a first closing of $45 million. Philadelphia-based New Rhein Healthcare Investors led the round, with wide participat ..read more

American Injectables Inc., a developer and manufacturer of sterile injectable parenteral drugs located in Tampa Bay, FL today announced the expansion of the leadership team with the hiring of Adam Levitt as CEO, Gilad Shadur as CFO and Alison Brown as VP Quality, further strengthening the leadership team after the addition of Ben Boling as COO last year. Adam Levitt becomes the CEO effective 1 August 2021. Adam was already a board member for the company, making this a smooth leadership transition. Adam will have strategic and operational responsibility for American Injectables and will report ..read more

Its Next Generation Medical Device to Noninvasively Treat BPH The new device changes the treatment paradigm for enlarged prostate patients, with a non-surgical procedure completed under local anaesthesia in less than ten minutes in the urologist’s office Butterfly Medical, today announced that its next generation device to reduce or eliminate benign prostatic hyperplasia (BPH) symptoms has obtained European CE Mark approval. BPH is a condition where the prostate enlarges and is highly prevalent in men, 50+ years old. Its symptoms often include problems urinating, urgency to urinate, getting-up ..read more

· New Rhein sells respiratory company Softhale to Sino Biopharm for upfront consideration of USD 110 million plus profit share · During New Rhein’s tenure, Softhale transitioned from a medical technology start-up into a highly specialised pharmaceutical developer of inhalation medicines · New Rhein has supported Softhale in accelerating the development of a novel proprietary platform of inhalation devices to treat respiratory diseases more effectively Philadelphia/Brussels, 23 March 2021 – New Rhein Healthcare Investors announced that it has agreed to sell its 60% stake in Softhale NV to Sino ..read more